The Eastern Cooperative Oncology Group (ECOG) is a multidisciplinary cancer clinical trials research group dedicated to the treatment, prevention, and cure of adult malignancies. The Operations Office grant application requests funding to support the activities of the group headquarters. Under the direction of the Principal Investigator, Robert L. Comis, MD, the ECOG Operations office is responsible for organizing and coordinating the scientific and administrative activities of the Group;these activities include protocol development, correlative study development, dissemination of necessary information to Group members, organization of Group meetings, maintenance of Group membership and publications, monitoring of compliance with regulatory requirements, adverse event (AE) reporting and review, administration of the audit program, the development and maintenance of standard operating procedures (SOPs), and the management and disbursement of Group funds. Funding requested by the ECOG Operations Office Grant includes support for the Chairs of the ECOG Scientific and Administrative Committees. Additionally funding is requested in this application for member institution accruals to therapeutic and non-therapeutic clinical trials. This application requests funding for the period 05/01/2010 - 04/30/2016.

Public Health Relevance

The primary goal of the ECOG Operations Office is to provide the support necessary to conduct relevant and rigorous clinical trials, which benefit public health by improving the quality and standard of care for cancer patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA021115-37
Application #
8139882
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1992-09-01
Project End
2016-04-30
Budget Start
2011-05-01
Budget End
2012-04-30
Support Year
37
Fiscal Year
2011
Total Cost
$8,154,955
Indirect Cost
Name
Frontier Sci & Technology Rsch Fdn, Inc
Department
Type
DUNS #
080330186
City
Boston
State
MA
Country
United States
Zip Code
02215
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Sparano, Joseph A; Gray, Robert; Oktay, Maja H et al. (2017) A metastasis biomarker (MetaSite Breastâ„¢ Score) is associated with distant recurrence in hormone receptor-positive, HER2-negative early-stage breast cancer. NPJ Breast Cancer 3:42
Saha, Poornima; Regan, Meredith M; Pagani, Olivia et al. (2017) Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials. J Clin Oncol 35:3113-3122
Sekeres, Mikkael A; Othus, Megan; List, Alan F et al. (2017) Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol 35:2745-2753
Erbe, Amy K; Wang, Wei; Goldberg, Jacob et al. (2017) FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma. Clin Cancer Res 23:2159-2168
Zhou, Jun; Mahoney, Kathleen M; Giobbie-Hurder, Anita et al. (2017) Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade. Cancer Immunol Res 5:480-492
Holstein, Sarah A; Jung, Sin-Ho; Richardson, Paul G et al. (2017) Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol 4:e431-e442
Sebastian, Sinto; Zhu, Yuan X; Braggio, Esteban et al. (2017) Multiple myeloma cells' capacity to decompose H2O2 determines lenalidomide sensitivity. Blood 129:991-1007
Agarwala, Sanjiv S; Lee, Sandra J; Yip, Waiki et al. (2017) Phase III Randomized Study of 4 Weeks of High-Dose Interferon-?-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Gro J Clin Oncol 35:885-892
Garg, Madhur K; Zhao, Fengmin; Sparano, Joseph A et al. (2017) Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205). J Clin Oncol 35:718-726

Showing the most recent 10 out of 743 publications